To include your compound in the COVID-19 Resource Center, submit it here.

Inovio licenses preclinical immunotherapy vaccines to Roche

Inovio Pharmaceuticals Inc. (NYSE-M:INO) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to prostate cancer vaccine

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE